JPET #240564

Title Page

Methoxyluteolin inhibits neuropeptide-stimulated TNF, CXCL8 and VEGF release via mTOR activation from human mast cells

Arti B. Patel and Theoharis C. Theoharides

Molecular Immunopharmacology and Drug Discovery Laboratory, Department of Integrative Physiology and Pathobiology, Tufts University School of Medicine, Boston, MA, USA (A.B.P & T.C.T)

Graduate Program in Cell, Molecular and Developmental Biology, Sackler School of Graduate Biomedical Sciences, Tufts University, Boston, MA, USA (A.B.P)

Department of Internal Medicine, Tufts University School of Medicine and Tufts Medical Center, Boston, MA, USA (T.C.T)

Department of Psychiatry, Tufts University School of Medicine and Tufts Medical Center, Boston, MA, USA (T.C.T)

Running Title Page

Neuropeptide-stimulation of human mast cells via mTOR

Address for correspondence:

T.C. Theoharides, MS, MPhil, PhD, MD
Department of Integrative Physiology and Pathobiology
Tufts University School of Medicine
136 Harrison Avenue, Suite J 304
Boston, MA 02111, USA
Phone: (617) 636-6866
Fax   : (617) 636-2456
E-mail: theoharis.theoharides@tufts.edu

Document Statistics:

Number of Text Pages: 34
Number of Tables: 0
Number Figures: 5
Number of References: 88
Number of Words in the Abstract: 238
Number of Words in the Introduction: 1,332
Number of Words in the Discussion: 1,461

List on Non-standard Abbreviations:

corticotropin-releasing hormone (CRH); C-X-C motif chemokine ligand 8 (CXCL8); dimethyl sulfoxide (DMSO); Disodium cromoglycate (cromolyn); enzyme linked immunosorbent assay (ELISA); high affinity IgE receptor (FcεRI); ; luteolin (Lut); LY294002 (LY); mammalian target of rapamycin complex 1 (mTORC1); mammalian target of rapamycin complex 2 (mTORC2); mast cell (MC); ; 3',4',5,7-tetramethoxyluteolin (Methlut); neurotensin (NT); nuclear factor-kappa B (NF-κB); phosphatase and tensin homolog (PTEN); phosphorylation (p); phosphoinositide 3-kinase (PI3K); Rapamycin (Rap); Recombinant human stem cell factor (rhSCF); ribosomal p70S6 kinase (p70S6K); substance P (SP); tris-buffered saline (TBS); tumor necrosis factor (TNF); vascular endothelial growth factor (VEGF); soluble N-ethylmaleimide-sensitive factor attachment proteins (SNARE complexes); signal transducer and activator of transcription (STAT); 4E-binding protein 1 (4EBP1)

Abstract

Mast cells (MC) are critical for allergic reactions, but are also important in inflammatory processes. Stimulation by neuropeptides, such as substance P (SP) and neurotensin (NT) leads to release of pre-formed molecules stored in numerous MC secretory granules and newly-synthesized pro-inflammatory mediators, including tumor necrosis factor (TNF), interleukin 8 (CXCL8) and vascular endothelial growth factor (VEGF). Here, we investigate the role of mammalian target of rapamycin (mTOR) signaling in the stimulation of cultured human LAD2 MC by NT or SP, and the inhibitory effect of the natural flavonoids 3',4',5,7-tetrahydroxyflavone (luteolin) and its novel structural analog 3',4',5,7-tetramethoxyluteolin (methoxyluteolin). Stimulation by NT (10 µM) or SP (1 µM) increases ($p<0.0001$) the gene expression (after 6 h) and release (after 24 h) of TNF, CXCL8 and VEGF. This occurs via activation of both mTOR complexes, as denoted by the increased phosphorylated (p) protein levels ($p<0.0001$) of the downstream mTORC1 substrate pp70S6KThr389 and mTORC2 component pmTORSer2448. Pre-treatment of human MC using the mTORC1 inhibitor rapamycin or the mTORC1/mTORC2 inhibitor Torin1 or the two flavonoids decreases both gene expression and release ($p<0.0001$) of all three mediators. Methoxyluteolin is more potent human MC inhibitor than luteolin or Torin1, implicating other MC protein targets in addition to the mTOR complex. The present findings indicate that mTOR is partially involved in the neuropeptide-stimulation of MC, but the novel flavonoid methoxyluteolin inhibits the response entirely, suggesting that it may be developed for treatment of allergic and inflammatory diseases.

Introduction

Mast cells (MC) are unique immune cells that derive from hematopoietic precursors and mature in vascularized tissues (Rodewald, et al., 1996;Kitamura and Ito, 2005;Schmetzer, et al., 2016). In addition to stimulation by the high affinity IgE receptor (FcεRI) (Rivera, et al., 2008), MC are also activated by bacterial endotoxins, such as lipopolysaccharides via the toll-like receptors (Palaska, et al., 2016) and neuropeptides such as neurotensin (NT) (Lazarus, et al., 1977;Kulka, et al., 2007) and substance P (SP) (Church, et al., 1991;Theoharides, et al., 2010), Stimulated MC release pre-stored molecules, including histamine, heparin and tryptase, as well as *de novo* synthesized pro-inflammatory mediators, such as tumor necrosis factor (TNF), interleukin-8 (CXCL8) and vascular endothelial growth factor (VEGF) (Theoharides, et al., 2012). As a result, MC are not only involved in allergies (Galli and Tsai, 2012), but also in immunity (Galli, et al., 2008), mast cell disorders, including mastocytosis (Theoharides, et al., 2015), and inflammatory diseases (Theoharides and Cochrane, 2004;Theoharides, et al., 2012).

The neuropeptides SP (Chang and Leeman, 1970) and NT (Carraway and Leeman, 1973), initially characterized by Leeman and colleagues, are implicated in inflammatory processes (Mashaghi, et al., 2016). Increased levels of SP have been associated with inflammatory diseases (O'Connor, et al., 2004) and the cross-talk between endocrinology system and skin (Caraffa, et al., 2016), leading to disorders, such as psoriasis (Remröd, et al., 2007).Circulating levels of NT have been reported in patients with psoriasis and atopic dermatitis (Vasiadi M, et al., 2012). MC-derived CXCL8 enhances recruitment of immune cells to the site of inflammation (Salamon, et al., 2005), while VEGF can increase vascular permeability (Donelan, et al., 2006). Even though the allergic stimulation of MC is fairly well characterized (Rivera, et al., 2008), less is known about the stimulation of MC by neuropeptides. A receptor (Mrgprx2) was recently identified as being critical in pseudo-allergies, some of which

are due to MC activation by cationic drugs and molecules (McNeil, et al., 2015), but NT and SP were not studied.

The phosphatidylinositol-3-kinase (PI3K)-dependent mammalian target of rapamycin (mTOR) kinase pathway (Dibble and Cantley, 2015) has been implicated in the regulation of normal MC homeostasis and function (Kim, et al., 2008a), including FcεRI-mediated allergic responses (Smrz, et al., 2011), but has not been studied in neuropeptide-stimulated MC. The mTOR catalytic subunits exists in two complexes: (a) mTORC1, involved in protein translational control by phosphorylation of ribosomal S6 kinases (S6K) and the eukaryotic initiation factor 4E-binding proteins (4EBP1), and (b) mTORC2 implicated in cytoskeleton reorganization (Laplante and Sabatini, 2012). It was previously shown that mTORC1 is involved in the allergic stimulation of MC (Kim, et al., 2008b) and is constitutively activated in cultured human LAD2 MC (Kim, et al., 2008a). Other studies have revealed that mTORC2 mediates MC chemotaxis (Kuehn, et al., 2011) and proliferation of neoplastic human MC (Smrz, et al., 2011). Downregulation of the upstream mTOR inhibitory protein phosphatase and tensin homolog (PTEN) leads to increased MC activation (Furumoto, et al., 2006) and a mastocytosis-like state (Furumoto, et al., 2011).

There are still no clinically effective MC inhibitors (Theoharides, et al., 2012;Finn and Walsh, 2013). Disodium cromoglycate (cromolyn) is known as a "MC stabilizer" because it inhibits rodent peritoneal MC histamine release (Theoharides, et al., 1980), but it does not effectively inhibit either murine MC (Oka, et al., 2012) or human MC (Weng, et al., 2012). Even though the local application of an experimental cromolyn ointment reduced histamine-induced pruritus in human skin, it apparently did so via modulation of sensory nerves and not by inhibiting MC (Vieira Dos, et al., 2010). Moreover, inhibitors of the tyrosine kinase c-kit receptor that reduce MC proliferation (Heinrich, et al., 2000) do not inhibit MC activation (Gotlib, et al., 2016). Tacrolimus was developed as an mTOR inhibitor for skin inflammatory diseases (Michel, et al., 1996), but it has been associated with allergic responses (Beck, 2005). Hence, there is an

urgent need for developing effective inhibitors of human MC. The natural flavonoid 3,5,7,3',4'-pentahydroxyflavone (quercetin) has been shown to be more potent than cromolyn in inhibiting photosensitivity in humans (Weng, et al., 2012). Quercetin (Mlcek, et al., 2016) and 3',4',5,7-tetrahydroxyflavone (luteolin) are natural anti-oxidant and anti-inflammatory flavonoids (Middleton, et al., 2000), which also inhibit MC histamine, TNF and VEGF (Kempuraj, et al., 2005), as well as release of leukotrienes and prostaglandin D2 (Kimata, et al., 2000). We recently showed that its structural analog, 3',4',5,7-tetramethoxyflavone (methoxyluteolin) is a more potent MC inhibitor (Weng, et al., 2015) and is also metabolically more stable (Walle, 2007).

In the present study, we report that mTOR activation is involved in the stimulation of human MC by the neuropeptides NT and SP, and that this mechanism is inhibited by the flavonoids luteolin and methoxyluteolin.

Methods

Materials

SP (S6883) and NT (N6383) were obtained from Sigma-Aldrich (St Louis, MO). PI3K inhibitor LY294002 (Cell Signaling Technology/CST, Danvers, MA) and mTOR inhibitors (rapamycin and Torin 1 (TOCRIS biosciences, Bristol, UK) were purchased. The flavonoids luteolin and methoxyluteolin were obtained from Pharmascience Nutrients (Clear Water, FL). RNeasy Mini (Qiagen Inc., Valencia, CA) and iScript cDNA synthesis kits (BioRad, Hercules, CA) were purchased. Taqman gene expression primers/assays for TNF (Hs99999043_m1), CXCL8 (Hs00174103_m1), VEGFA (Hs00900055_m1) and GAPDH endogenous control (4310884E) were purchased from Applied Biosystems (ThermoFisher Scientific, Foster City, CA). ELISA kits for TNF (DY210), CXCL8 (DY208) and VEGF (DY293B) were purchased from R&D Biosystems (Minneapolis, MN). Rabbit mAb for mTOR (7C10), pmTORSer2448 (D9C2), pmTORSer2481, mTORC1 substrates p70S6K (49D7), pp70SK Thr389 (108D2), 4EBP1 (53H11) and p4EBP1Thr37/46 (236B4), as well as the loading control β-actin (D6A8) were purchased from Cell Signaling Technology.

Human MC Culture

Human LAD2 MC (kindly supplied by Dr. A.S. Kirshenbaum, National Institutes of Health, NIH), derived from human MC leukemia (Kirshenbaum, et al., 2003), were cultured in StemPro®-34 SFM medium (Invitrogen, Carlsbad, CA) supplemented with 100 U.mL^{-1} penicillin/streptomycin and 100 ng.mL^{-1} recombinant human stem cell factor (rhSCF, kindly supplied by Biovitrum AB, Stockholm, Sweden). These cells have been used numerous times in our laboratory and shown to behave like primary human umbilical-cord blood derived MC. Cell viability was determined by trypan blue (0.4 %) exclusion.

LAD2 MC Treatments

LAD2 MC were stimulated with NT (1-10 μM, Sigma-Aldrich, St. Louis, MO) or SP (1 μM, Sigma-Aldrich) and/or pre-incubated with DMSO or the following inhibitors: (a) PI3K inhibitors (LY294002 (LY), 1-10 μM, 2h, Cell Signaling Technology), (b) mTOR inhibitors (rapamycin (Rap), 0.005-0.2 μM or Torin1, 0.005-0.2 μM TOCRIS biosciences, Bristol, UK) and (c) the flavonoids (luteolin or methoxyluteolin, 1-50 μM, 2, 12 or 24 h, PharmaScience Nutrients, Clearwater, FL). All inhibitors were dissolved in water or DMSO with final concentration of < 0.1 %.

Pro-inflammatory Mediator Release by ELISA

Mediator release in cell-conditioned culture medium/ supernatant fluid was determined by using commercial available ELISA kits (R&D Systems, Minneapolis, MN) as per manufacturer's instructions. LAD2 MC (0.5×10^6 cells/well) were seeded in 96-well flat-bottom Falcon Culture plates (Becton Dickinson) prior to pretreatment with inhibitors/flavonoids (for 30 min) and NT- or SP-stimulation for 24 h. MC supernatant fluids were collected and TNF, CXCL8 and VEGF mediator release was measured. For all experiments, the control cells were treated with equal volume of culture medium or DMSO, and the minimum detectable level for all by ELISA was 5 pg.mL^{-1}.

MC Degranulation

LAD2 MC were stimulated with the neuropeptides, NT (10 μM, Sigma-Aldrich) or substance P (SP 1 μM, Sigma-Aldrich) for 30 min. Beta-hexosaminidase release was assayed using a fluorometric method as previously reported (Weng, et al., 2015). Briefly, beta-hexosaminidase activity in the supernatant fluid and cell lysates (0.5×10^5 cells per tube, were lysed with 1% Triton X-100 to measure residual cell-associated beta-hexosaminidase) were incubated with substrate solution (p-nitrophenyl-N-acetyl-beta-D-glucosaminide from Sigma-

Aldrich) in 0.1 M NaOH/0.2 M glycine. Absorbance was read at 405 nm in a plate reader (Lab Systems Multiskan RC, Thermo Fisher), and the results were expressed as percentage of beta-hexosaminidase released over the total.

Pro-inflammatory Mediator Gene Expression by qRT-PCR

Total RNA from LAD2 MC was isolated using RNeasy Mini Kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. Reverse transcription (RT) was performed with 300 ng of total RNA using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA). Gene expression analysis of TNF, CXCL8 and VEGF mediators in LAD2 MC (1×10^6 cells per 6-well plate), those pre-incubated with inhibitors/flavonoids and/or those stimulated with NT or SP, was measured after 6 h. Quantitative real-time PCR (qRT-PCR) was performed using Taqman gene expression assays to assess the gene expression of mediators using validated oligonucleotide primers (Applied Biosystems, Carlsbad, CA). Samples were run at 45 cycles using Applied Biosystems 7300 Real-Time PCR System. Relative mRNA abundance was determined from standard curves run for each experiment. Gene expression was normalized to GAPDH endogenous control.

Assessing mTOR Activation by Western blot & ELISA

The activation of mTOR was assessed by phosphorylation (p) of downstream mTORC1 and mTORC2 substrates by Western blot analysis and using Pathscan phospho-ELISA kits (R&D Systems). LAD2 MC (1×10^6 cells per flask) were pretreated with inhibitors or flavonoids for the indicated doses and times, then stimulated with NT or SP for 0-60 mins. Thereafter, cells were pelleted and lysates harvested in radioimmunoprecipitation assay buffer (Sigma Aldrich), containing Halt Protease and Phosphatase Inhibitor Cocktails (Thermo Fisher Sci., Rockford, IL). The total protein concentrations were determined by the bicinchoninic acid assay (Thermo Fisher Sci.) using bovine serum albumin protein as standards. The total proteins (20 or 40 µg)

were separated using 4-20 % Mini-PROTEAN TGX™ precast gels (BioRad) under SDS denaturing conditions and electro-transferred onto PVDF membranes (EMD Millipore). Blocking was carried out with 5% (wt/vol) BSA in Tris-buffered saline (TBS) containing 0.1 % Tween-20. The membranes were probed with the following primary antibodies: mTOR (7C10), pmTOR (Ser2448), mTORC1 substrates p70S6K, pp70SK (Thr389), 4EBP1 and p4EBP1 (Thr-37/46), while β-actin served as the loading control (Cell Signaling Technology/ CST, Danvers, MA). All proteins were visualized with horseradish peroxidase-conjugated secondary antibodies and then by SuperSignal West Pico enhanced chemiluminescence (Thermo Fisher Sci). To quantitate changes in protein phosphorylation, the films were scanned and densitometric analysis will be carried out using Image J software. In parallel experiments, using the CST's PathScan mTOR, pmTOR (Ser2448), p70S6K, pp70S6K (Thr389), 4EBP1 and p4EBP1 sandwich ELISA kits, the levels of total and phosphorylated mTORC1 substrates were measured in MC after treatments described.

Statistical Analysis

All conditions were performed in triplicate and all experiments were repeated at least three times (n=3). Results from cultured cells are presented as mean ± SD. Comparisons were made between (1) control and stimulated cells using the unpaired 2-tailed, Student's *t*-test, with significance denoted by the horizontal lines and by $p < 0.05$ (*), $p < 0.001$ (**) and $p < 0.0001$ (***). In addition, multiple comparisons were made between (2) stimulated cells without inhibitors/flavonoids (DMSO or buffer control) and those with inhibitors/flavonoids using one-way ANOVA, followed by post-hoc analysis by Dunnett's Multiple Comparison Test; significance is denoted by horizontal lines and indicated values $p < 0.001$ or $p < 0.0001$ and (3) all the condition with inhibitor/flavonoid among themselves using one-way ANOVA, followed by post-hoc analysis by Tukey's Multiple Comparison Test; those conditions for which there was significance is denoted by the horizontal brackets and by the corresponding $p < 0.05$ (*), $p < 0.001$ (**) and

p<0.0001 (***). All statistical analyses were performed by using the GraphPad Prism version 5.0

software (GraphPad Software, San Diego, CA, USA). Representative images for western blots

were scanned and analyzed using Image J (NIH; https://imagej.nih.gov/ij/).

Results

Neuropeptide-stimulated human MC pro-inflammatory mediator release is inhibited by PI3K or mTOR inhibitors.

Initially, we investigated the optimal concentrations of NT or SP (1-10 µM) that stimulated the *de novo* pro-inflammatory mediator release from cultured human LAD2 MC. Stimulation by NT (10 µM) and SP (1 µM) significantly increased the release of TNF, CXCL8 and VEGF from human LAD2 MC after 24 h. Using these optimal concentrations, we next evaluated the involvement of mTOR signaling by employing pharmacological inhibitors of mTOR, which included the bacterial macrolide and more selective mTORC1 inhibitor rapamycin and the more potent ATP-competitive dual inhibitor of mTOR, Torin1, as well as the upstream PI3K inhibitor LY294002.

Pre-treatment of LAD2 MC (24 h) with the inhibitors of mTOR signaling, rapamycin and Torin1, dose-dependently (0.05-0.2 µM) decreases SP-stimulated TNF **(Fig. 1A)** and CXCL8 **(Fig. 1B)** release from human MC. At the optimal inhibitory concentration of 0.2 µM, Torin1 significantly decreases ($p<0.001$) pro-inflammatory mediator release from SP-stimulated LAD2 MC, as compared to rapamycin that is more selective for mTORC1 inhibition. Pre-treatment with the PI3K inhibitor, LY294002 (1-10 µM, 2 h) decreases ($p<0.0001$) TNF and CXCL8 release, with optimal inhibitory concentration of 10 µM **(Fig. 1C)**.

Neuropeptide-stimulated human MC degranulation is decreased by the PI3K inhibitor and the flavonoids luteolin and methoxyluteolin, but not mTOR inhibitors

Unlike their effect on *de novo* synthesized mediator release, pre-treatment of LAD2 MC with the mTOR inhibitors (rapamycin or Torin1, 0.2 µM, 24 h), followed by stimulation with either NT **(Suppl. Fig. 1A)** or SP **(Suppl. Fig. 1B)** for 30 min had no effect on β-hexosaminidase release from LAD2 MC. The upstream PI3K inhibitor (LY294002, 10 µM, 2 h) or the flavonoids

12

luteolin and methoxyluteolin also had no effect on β-hexosaminidase release from LAD2 MC at 10 μM; however, all three compounds significantly decrease (p<0.001), β-hexosaminidase release at 50 μM, when used for 24 h **(Suppl. Fig. 1)**.

Neuropeptide-stimulated human MC pro-inflammatory mediator release is inhibited by the flavonoids luteolin and methoxyluteolin.

LAD2 MC were first pre-treated with luteolin and methoxyluteolin at various doses (1-50 μM, 2 h), then stimulated by NT (10 μM) for 24 h to identify the most effective concentration inhibiting release of pro-inflammatory mediators. Methoxyluteolin more potently than luteolin (p<0.001) decreases the release of all mediators at equimolar flavonoid concentrations **(Suppl. Fig. 2)**. We further compared the effects of the PI3K/mTOR inhibitors to the flavonoids luteolin and methoxyluteolin on LAD2 MC mediator release after neuropeptide stimulation for 24 h. LAD2 MC were pre-treated with inhibitors of mTOR (rapamycin or Torin 1, 0.2 μM, 24 h) or PI3K (10 μM, 2h) and the flavonoids luteolin or methoxyluteolin (50 μM, 2 h), and then stimulated by NT (10 μM) or SP (1 μM) for 24 h. The release of TNF, CXCL8 and VEGF significantly decreases in the presence of the flavonoids (p<0.0001), after stimulation by either NT **(Fig. 2A-C)** or SP **(Fig. 2D-F)**.

Neuropeptide-stimulated pro-inflammatory mediator gene expression in human MC is decreased by the PI3K or mTOR inhibitors, as well as luteolin and methoxyluteolin.

We further investigated whether mTOR signaling is involved in the gene transcription of pro-inflammatory mediators in human MC stimulated by either NT or SP. LAD2 MC were pretreated with the mTOR inhibitors rapamycin and Torin1 (0.2 μM, 24 h) and the upstream PI3K inhibitor LY294002 (10 μM, 2 h), prior to stimulation with NT (10 μM) or SP (1 μM) for 6 h. Stimulation of LAD2 MC by either NT **(Fig. 3A-C)** or SP **(Fig. 3D-F)** significantly increases

(p<0.001) the gene expression of TNF, CXCL8 and VEGF, which decreases (p<0.0001) after treatment with the PI3K/mTOR inhibitors **(Fig. 3)**.

Pre-treatment with either luteolin or methoxyluteolin also significantly decreases (p<0.0001) gene expression of TNF, CXCL8 and VEGF in response to NT or SP **(Fig. 3)**. Methoxyluteolin (50 µM) is more potent (p<0.05) than luteolin or the PI3K inhibitor LY294002 (p<0.001) for inhibition of TNF and CXCL8, but not for VEGF gene expression **(Fig. 3C and 3F)**.

Neuropeptide stimulation of human MC activates signaling via mTOR that is inhibited by methoxyluteolin.

To investigate the specific mTOR complex activated in response to NT or SP stimulation, Western blot analysis was performed to detect the total and phosphorylated (p) levels of mTOR (pmTORSer2448, an indicator of signaling via mTORC2) and the mTORC1 substrates p70S6K (pp70S6KThr389) and 4EBP1 (p4EBP1Thr37/46) proteins **(Fig. 4A)**. Densitometric analysis revealed that stimulation of LAD2 MC with either NT (10 µM) or SP (1 µM) increases (p<0.0001) the levels of pmTORSer2448 **(Fig. 4A and 4D)** and the downstream mTORC1 substrate, pp70S6KThr389 **(Fig. 4B and 4E)** after 20 min, when compared to control cells. Noteworthy, stimulation with NT or SP had no effect on the levels of p4EBP1Thr37/46, as shown by Western blot **(Fig. 4C and 4F)**.

Since, PI3K upstream of mTOR signaling has been implicated in activation of MC (Kim, et al., 2008b), we further evaluated the inhibitory effects of luteolin and methoxyluteolin on mTOR in NT or SP stimulated LAD2 MC. LAD2 MC were pre-incubated with rapamycin or Torin 1 (0.2 µM, 24 h) or LY294002 (10 µM, 2 h) or luteolin and methoxyluteolin (50 µM, 2 h) prior to NT (10 µM) **(Fig. 5A-C)** or SP (1 µM) **(Fig. 5D-F)** stimulation for 20 min. The PI3K/mTOR and the flavonoids inhibitors significantly decrease levels of pmTORSer2448 and pp70S6KThr389, compared to those of neuropeptide-stimulated LAD2 MC.

To further quantify the levels of phosphorylated mTOR and its substrates, phospho-ELISAs were also performed on LAD2 MC pre-treated with the PI3K/mTOR inhibitors or luteolin and methoxyluteolin, prior to stimulation with NT or SP. Levels of pmTOR Ser2448 (**Fig. 5A and 5D)** and pp70S6K Thr389 proteins **(Fig. 5B and 5E)** increase in response to stimulation with NT or SP, but significantly decrease ($p<0.001$) after pre-treatment with all the inhibitors. Noteworthy, methoxyluteolin shows greater reduction of pmTORSer2448 and pp70S6KThr389 levels, when compared to the PI3K inhibitor LY294002 ($p<0.0001$) or luteolin at equimolar flavonoid concentrations ($p<0.001$) **(Fig. 5).**

15

Discussion

A novel finding reported here is the involvement of mTOR signaling in the synthesis and release of TNF, CXCL8 and VEGF from cultured human MC in response to stimulation by neuropeptides. Stimulation of LAD2 MC by either NT or SP markedly increases levels of pmTORSer2448, the mTOR site phosphorylated by upstream PI3K signaling and the mTORC1-dependent p70S6K Thr389 site, indicating activation of mTOR. In addition, the dual mTORC1 and mTORC2 inhibitor, Torin1 is more potent than the predominant mTORC1 inhibitor rapamycin suggesting that both complexes may be involved in TNF, VEGF and CXCL8 gene expression in LAD2 MC. Our results are also in agreement with the previous report that rapamycin blocks FcɛRI-mediated PI3K-dependent activation of mTORC1 signaling and *de novo* synthesized IL-6 and CXCL8 release from murine MC (Kim, et al., 2008b).

Signaling via mTORC1 had previously been implicated in FcɛRI-mediated allergic cytokine release (Smrz, et al., 2011) and in the regulation of normal MC homeostasis (Kim, et al., 2008a).In fact, constitutively activated mTORC1 (Kim, et al., 2008a) is critical for the survival of LAD2 MC (Smrz, et al., 2011). Even though LAD2 MC derive from a patient with MC leukemia (Kirshenbaum, et al., 2003), these cells have repeatedly been shown to behave like primary human MC (Guhl, et al., 2010;Zhang, et al., 2012a;Weng, et al., 2015). One could argue that the findings presented here should be validated in primary human MC and in some mouse model. However, normal primary MC derived from skin were recently shown to have enormous variability in the responsiveness (Theoharides TC, 2016) and murine models are now considered to poorly mimic human inflammatory diseases (Seok, et al., 2013).

In order to allow for the de novo synthesis of TNF, CXCL8 and VEGF in human mast cells stimulated by either SP or NT, pro-inflammatory mediator gene expression was measured after 6 h, while mediator protein release was measured after 24 h to enable protein translation

and secretion from MC. An important new finding reported here is that the flavonoid methoxyluteolin significantly inhibits *gene* expression and release of all the pro-inflammatory mediators, as well as activation of mTOR. Moreover, methoxyluteolin is more potent than luteolin, rapamycin or Torin1. These findings suggest that mTOR signaling is involved in the transcriptional regulation of mediator induction in human LAD2 MC in response to stimulation by NT and SP. Luteolin had been shown to inhibit nuclear factor-kappa B (NF-κB)-mediated pro-inflammatory TNF synthesis in murine macrophages (Xagorari, et al., 2001), while our laboratory had previously shown that methoxyluteolin inhibits the SP-stimulated TNF release from LAD2 MC and induction of nuclear factor-kappa B (NF-κB) (Weng, et al., 2015). Hence, we speculate that methoxyluteolin could target inhibition of PI3K/mTOR signaling that is upstream of NF-κB (Dan, et al., 2008) and/or the signal transducer and activator of transcription (STAT) (Laplante and Sabatini, 2013;Saleiro and Platanias, 2015), and in effect inhibit these critical transcriptional regulators of pro-inflammatory cytokines and chemokines (Weichhart, et al., 2008). In fact, PI3K/mTOR, NF-κB and STAT have all been implicated in FcεRI-mediated allergic activation of human MC (Kim, et al., 2008b;Blatt, et al., 2012;Siegel, et al., 2013), while rapamycin was previously shown to inhibit TNF gene expression in rat MC (Park, et al., 2012).

Unlike the mTOR inhibitors, luteolin and methoxyluteolin also inhibit MC degranulation. This inhibition is even better than that of the PI3K inhibitor LY294002, which is known to be involved in the regulation of MC degranulation (Takayama, et al., 2013). Instead, the preferential mTORC1 inhibitor, rapamycin and the dual mTORC1/mTORC2 inhibitor, Torin 1 did not inhibit NT or SP-stimulated human MC degranulation, which is in agreement with the recent report showing that FcεRI-mediated allergic MC degranulation is regulated by the rictor protein alone, and not via the intact mTORC2 signaling (Smrz, et al., 2014). Our findings suggest that the flavonoids luteolin and methoxyluteolin could target inhibition of MC degranulation in an mTOR-independent manner. One such mechanism could involve inhibition of intracellular calcium

levels in human MC, which is required for activation of PI3K and other signaling proteins, such as phospholipase C (Gilfillan and Rivera, 2009) and contributes to the regulation of granule exocytosis (Holowka, et al., 2012). We had previously shown that methoxyluteolin inhibits intracellular calcium levels in human MC (Weng, et al., 2015). Additionally, the flavonoids could target specific proteins involved in vesicle fusion, such as soluble N-ethylmaleimide-sensitive factor attachment proteins (SNARE complexes) (Yang, et al., 2015), implicated in MC degranulation.

Patients with systemic mastocytosis (Metcalfe and Akin, 2001;Theoharides, et al., 2015) have increased mTOR gene expression in bone marrow mononuclear cells (Smrz, et al., 2011) and it has been suggested that selectively targeting mTOR complexes could effectively reduce proliferation of MC associated with inflammation and MC disorders. Rapamycin had already been reported to inhibit the survival of KIT D816V mutated MC in culture (Gabillot-Carre, et al., 2006), a mutation characteristic in almost 80% of patients with systemic mastocytosis, rendering the encoded tyrosine kinase receptor and mTOR constitutively active. However, treatment using everolimus, an oral mTOR inhibitor, resulted in toxicity and side-effects in patients with systemic mastocytosis (Parikh, et al., 2010). More recently, dual inhibitors of PI3K/mTOR that inhibit activation of neoplastic human MC (Blatt, et al., 2012) have been proposed as a treatment of systemic mastocytosis, but could have and poor tolerability. In addition to treating mastocytosis (Metcalfe and Akin, 2001;Theoharides, et al., 2015), methoxyluteolin could also be used for asthma (Galli and Tsai, 2012), atopic dermatitis, (Vasiadi M, et al., 2012) and psoriasis (Theoharides, et al., 2012).

The present findings of neuroimmunoendocrine interactions involving the neuropeptides NT and SP, and activation of MC could be important in the pathology of skin disorders (Caraffa, et al., 2016). For instance, activation of human MC via FcεRI up-regulates the surface expression of the SP neurokinin receptors (Kulka, et al., 2007). We had shown that SP (Asadi,

18

et al., 2012) and NT (Alysandratos, et al., 2012) induce the expression of corticotropin-releasing hormone (CRH) receptor-1 in human MC, through which NT synergistically with CRH stimulates VEGF release (Donelan, et al., 2006) and MC degranulation (Pang, et al., 1998). LAD2 MC express the NT receptor 1 (Alysandratos, et al., 2012), while other human MC lines also synthesize precursor NT peptides (Cochrane, et al., 2011). MC can also degrade NT (Piliponsky, et al., 2008), indicating tight regulation. Moreover, SP induces adhesion molecules on endothelial cells resulting in infiltration of other immune cells such as neutrophils and eosinophils (Quinlan, et al., 1999). Hence, the elevated circulating levels of SP and/or NT in patients with psoriasis and atopic dermatitis (Vasiadi M, et al., 2012) could have relevance in pathophysiological settings. Furthermore, we recently reported increased levels of TNF, SP and the SP-structural analog hemokinin A in patients with fibromyalgia syndrome (Tsilioni, et al., 2016). Interestingly, hemokinin A was reported to be secreted from rodent MC and have an autocrine action on MC (Sumpter, et al., 2015).

The ability of NT to stimulate mTOR activation in MC reported here is additionally intriguing given the increased levels of NT in patients with ASD (Angelidou, et al., 2010;Tsilioni, et al., 2014), who also have skin allergies (Theoharides, et al., 2016). Communication between MC and microglia has been invoked in inflammation of the brain (Skaper, et al., 2014) and increasing evidence indicates that MC and inflammation of the brain (Esposito, et al., 2002) are involved in the pathogenesis of ASD (Theoharides, et al., 2016). Microglia, the resident immune cells of the brain are stimulated by MC-derived histamine (Dong, et al., 2014) and tryptase (Zhang, et al., 2012b). Moreover, about 1-5% of ASD cases have gene mutations in regulatory proteins upstream of mTOR (Willsey and State MW, 2015), removing any innate inhibition of this signaling complex. We recently showed that NT can stimulate cultured human microglia, an action inhibited by methoxyluteolin (Patel, et al., 2016).

Our present findings of mTOR activation in neuropeptide-stimulated MC and its inhibition by methoxyluteolin have clear therapeutic potential. In fact, two open-label clinical studies have reported that a luteolin-containing dietary formulation significantly improved attention and sociability in children with ASD (Theoharides T.C., et al., 2012;Taliou, et al., 2013), while a combination of luteolin with palmitoylethanolamide was further reported to have significant benefit in cerebral ischemia in humans (Caltagirone, et al., 2016). Therapeutically, methoxyluteolin could be superior to luteolin for treating patients with mast cell disorders not only because it is a more potent inhibitor of MC and mTOR activation, but its four additional methyl groups, as compared to luteolin, increases its solubility, absorption and metabolic stability (Walle, 2007). Moreover, since flavonoids typically have low oral bioavailability of less than 10 % in humans (Williamson and Manach, 2005), utilizing novel drug delivery systems, such as encapsulation of methoxyluteolin into liposomes coated with a targeting ligand could improve bioavailability and enhance delivery to sites of inflammation, where activated MC are present.

Acknowledgments

JPET #240564

Authorship contributions

Participated in research design: Patel, Theoharides

Conducted experiments & performed data analysis: Patel

Wrote or contributed to the writing of the manuscript: Patel, Theoharides

References

Alysandratos KD, Asadi S, Angelidou A, Zhang B, Sismanopoulos N, Yang H, Critchfield A and Theoharides TC (2012) Neurotensin and CRH interactions augment human mast cell activation. *PloS One* **7**:e48934.

Angelidou A, Francis K, Vasiadi M, Alysandratos K-D, Zhang B, Theoharides A, Lykouras L, Kalogeromitros D and Theoharides T (2010) Neurotensin is increased in serum of young children with autistic disorder. *J Neuroinflam* **7**:48.

Asadi S, Alysandratos KD, Angelidou A, Miniati A, Sismanopoulos N, Vasiadi M, Zhang B, Kalogeromitros D and Theoharides TC (2012) Substance P (SP) induces expression of functional corticotropin-releasing hormone receptor-1 (CRHR-1) in human mast cells. *J Invest Dermatol* **132**:324-329.

Beck LA (2005) The efficacy and safety of tacrolimus ointment: a clinical review. *J Am Acad Dermatol* **53**:S165-S170.

Blatt K, Herrmann H, Mirkina I, Hadzijusufovic E, Peter B, Strommer S, Hoermann G, Mayerhofer M, Hoetzenecker K, Klepetko W, Ghanim V, Marth K, Fureder T, Wacheck V, Valenta R and Valent P (2012) The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils. *PloS One* **7**:e29925.

Caltagirone C, Cisari C, Schievano C, Di PR, Cordaro M, Bruschetta G, Esposito E and Cuzzocrea S (2016) Co-ultramicronized Palmitoylethanolamide/Luteolin in the Treatment of Cerebral Ischemia: from Rodent to Man. *Transl Stroke Res* **7**:54-69.

Caraffa A, Spinas E, Kritas SK, Lessiani G, Ronconi G, Saggini A, Antinolfi P, Pizzicannella J, Toniato E, Theoharides TC and Conti P (2016) Endocrinology of the skin: intradermal neuroimmune network, a new frontier. *J Biol Regul Homeost Agents* **30**:339-343.

Carraway R and Leeman SE (1973) The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. *J Biol Chem* **248**:6854-6861.

Chang MM and Leeman SE (1970) Isolation of a sialogogic peptide from bovine hypothalamic tissue and its characterization as substance P. *J Biol Chem* **245**:4784-4790.

Church MK, el-Lati S and Caulfield JP (1991) Neuropeptide-induced secretion from human skin mast cells. *Int Arch Allergy Appl Immunol* **94**:310-318.

Cochrane DE, Carraway RE, Harrington K, Laudano M, Rawlings S and Feldberg RS (2011) HMC-1 human mast cells synthesize neurotensin (NT) precursor, secrete bioactive NT-like peptide(s) and express NT receptor NTS1. *Inflamm Res* **60**:1139-1151.

Dan HC, Cooper MJ, Cogswell PC, Duncan JA, Ting JP and Baldwin AS (2008) Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. *Genes Dev* **22**:1490-1500.

Dibble CC and Cantley LC (2015) Regulation of mTORC1 by PI3K signaling. *Trends Cell Biol* **9**: 545-555.

Donelan J, Boucher W, Papadopoulou N, Lytinas M, Papaliodis D and Theoharides TC (2006) Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process. *Proc Natl Acad Sci USA* **103**:7759-7764.

Dong H, Zhang W, Zeng X, Hu G, Zhang H, He S and Zhang S (2014) Histamine induces upregulated expression of histamine receptors and increases release of inflammatory mediators from microglia. *Mol Neurobiol* **49**:1487-1500.

Esposito P, Chandler N, Kandere-Grzybowska K, Basu S, Jacobson S, Connolly R, Tutor D and Theoharides TC (2002) Corticotropin-releasing hormone (CRH) and brain mast cells regulate blood-brain-barrier permeability induced by acute stress. *J Pharmacol Exp Ther* **303**:1061-1066.

Finn DF and Walsh JJ (2013) Twenty-first century mast cell stabilizers. *Br J Pharmacol* **170**:23-37.

Furumoto Y, Brooks S, Olivera A, Takagi Y, Miyagishi M, Taira K, Casellas R, Beaven MA, Gilfillan AM and Rivera J (2006) Cutting Edge: Lentiviral short hairpin RNA silencing of PTEN in human mast cells reveals constitutive signals that promote cytokine secretion and cell survival. *J Immunol* **176**:5167-5171.

Furumoto Y, Charles N, Olivera A, Leung WH, Dillahunt S, Sargent JL, Tinsley K, Odom S, Scott E, Wilson TM, Ghoreschi K, Kneilling M, Chen M, Lee DM, Bolland S and Rivera J (2011) PTEN deficiency in mast cells causes a mastocytosis-like proliferative disease that heightens allergic responses and vascular permeability. *Blood* **118**:5466-5475.

Gabillot-Carre M, Lepelletier Y, Humbert M, de SP, Hamouda NB, Zappulla JP, Liblau R, Ribadeau-Dumas A, Machavoine F, Letard S, Baude C, Hermant A, Yang Y, Vargaftig J, Bodemer C, Morelon E, Lortholary O, Recher C, Laurent G, Dy M, Arock M, Dubreuil P and Hermine O (2006) Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells. *Blood* **108**:1065-1072.

Galli SJ, Grimbaldeston M and Tsai M (2008) Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. *Nat Rev Immunol* **8**:478-486.

Galli SJ and Tsai M (2012) IgE and mast cells in allergic disease. *Nat Med* **18**:693-704.

Gilfillan AM and Rivera J (2009) The tyrosine kinase network regulating mast cell activation. *Immunol Rev* **228**:149-169.

Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, Awan FT, Hexner E, Mauro MJ, Sternberg DW, Villeneuve M, Huntsman LA, Stanek EJ, Hartmann K, Horny HP, Valent P and Reiter A (2016) Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. *N Engl J Med* **374**:2530-2541.

Guhl S, Babina M, Neou A, Zuberbier T and Artuc M (2010) Mast cell lines HMC-1 and LAD2 in comparison with mature human skin mast cells--drastically reduced levels of tryptase and chymase in mast cell lines. *Exp Dermatol* **19**:845-847.

24

Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA and Zigler AJ (2000) Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. *Blood* **96**:925-932.

Holowka D, Calloway N, Cohen R, Gadi D, Lee J, Smith NL and Baird B (2012) Roles for ca(2+) mobilization and its regulation in mast cell functions. *Front Immunol* **3**:104.

Kempuraj D, Madhappan B, Christodoulou S, Boucher W, Cao J, Papadopoulou N, Cetrulo CL and Theoharides TC (2005) Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. *Br J Pharmacol* **145**:934-944.

Kim MS, Kuehn HS, Metcalfe DD and Gilfillan AM (2008a) Activation and function of the mTORC1 pathway in mast cells. *J Immunol* **180**:4586-4595.

Kim MS, Radinger M and Gilfillan AM (2008b) The multiple roles of phosphoinositide 3-kinase in mast cell biology. *Trends Immunol* **29**:493-501.

Kimata M, Shichijo M, Miura T, Serizawa I, Inagaki N and Nagai H (2000) Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells. *Clin Exp Allergy* **30**:501-508.

Kirshenbaum AS, Akin C, Wu Y, Rottem M, Goff JP, Beaven MA, Rao VK and Metcalfe DD (2003) Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI. *Leuk Res* **27**:677-682.

Kitamura Y and Ito A (2005) Mast cell-committed progenitors. *Proc Natl Acad Sci U S A* **102**:11129-11130.

Kuehn HS, Jung MY, Beaven MA, Metcalfe DD and Gilfillan AM (2011) Prostaglandin E2 activates and utilizes mTORC2 as a central signaling locus for the regulation of mast cell chemotaxis and mediator release. *J Biol Chem* **286**:391-402.

Kulka M, Sheen CH, Tancowny BP, Grammer LC and Schleimer RP (2007) Neuropeptides activate human mast cell degranulation and chemokine production. *Immunology* **123**:398-410.

Laplante M and Sabatini DM (2012) mTOR signaling in growth control and disease. *Cell* **149**:274-293.

Laplante M and Sabatini DM (2013) Regulation of mTORC1 and its impact on gene expression at a glance. *J Cell Sci* **126**:1713-1719.

Lazarus LH, Perrin MH and Brown MR (1977) Mast cell binding of neurotensin; I. iodination of neurotensin and characterization of th interaction of neurotensin with mast cell receptor sites. *J Biol Chem* **252**:7174-7179.

Mashaghi A, Marmalidou A, Tehrani M, Grace PM, Pothoulakis C and Dana R (2016) Neuropeptide substance P and the immune response. *Cell Mol Life Sci* **73**:4249-4264.

McNeil BD, Pundir P, Meeker S, Han L, Undem BJ, Kulka M and Dong X (2015) Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. *Nature* **519**:237-241.

Metcalfe DD and Akin C (2001) Mastocytosis: molecular mechanisms and clinical disease heterogeneity. *Leuk Res* **25**:577-82.

Michel G, Kemeny L, Homey B and Ruzicka T (1996) FK506 in the treatment of inflammatory skin disease: promises and perspectives. *Immunol Today* **17**:106-108.

Middleton EJ, Kandaswami C and Theoharides TC (2000) The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer. *Pharmacol Rev* **52**:673-751.

Mlcek J, Jurikova T, Skrovankova S and Sochor J (2016) Quercetin and Its Anti-Allergic Immune Response. *Molecules* **21**.pii: E623

O'Connor TM, O'Connell J, O'Brien DI, Goode T, Bredin CP and Shanahan F (2004) The role of substance P in inflammatory disease. *J Cell Physiol* **201**:167-180.

Oka T, Kalesnikoff J, Starkl P, Tsai M and Galli SJ (2012) Evidence questioning cromolyn's effectiveness and selectivity as a 'mast cell stabilizer' in mice. *Lab Invest* **92**:1472-1482.

Palaska I, Gagari E and Theoharides TC (2016) The effects of P. gingivalis and E. coli LPS on the expression of proinflammatory mediators in human mast cells and their relevance to periodontal disease. *J Biol Regul Homeost Agents* **30**:655-664.

Pang X, Alexacos N, Letourneau R, Seretakis D, Gao W, Cochrane DE and Theoharides TC (1998) A neurotensin receptor antagonist inhibits acute immobilization stress-induced cardiac mast cell degranulation, a corticotropin-releasing hormone-dependent process. *J Pharm & Exp Therap* **287**:307-314.

Parikh SA, Kantarjian HM, Richie MA, Cortes JE and Verstovsek S (2010) Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis. *Leuk Lymphoma* **51**:269-274.

Park JW, Jeon YJ, Lee JC, Ahn SR, Ha SW, Bang SY, Park EK, Yi SA, Lee MG and Han JW (2012) Destabilization of TNF-alpha mRNA by Rapamycin. *Biomol Ther (Seoul)* **20**:43-49.

Patel AB, Tsilioni I, Leeman SE and Theoharides TC (2016) Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism. *Proc Natl Acad Sci U S A* **Sept 23**.pii:201604992.

Piliponsky AM, Chen CC, Nishimura T, Metz M, Rios EJ, Dobner PR, Wada E, Wada K, Zacharias S, Mohanasundaram UM, Faix JD, Abrink M, Pejler G, Pearl RG, Tsai M and Galli SJ (2008) Neurotensin increases mortality and mast cells reduce neurotensin levels in a mouse model of sepsis. *Nat Med* **14**:392-398.

Quinlan KL, Song IS, Naik SM, Letran EL, Olerud JE, Bunnett NW, Armstrong CA, Caughman SW and Ansel JC (1999) VCAM-1 expression on human dermal microvascular endothelial cells is directly and specifically up-regulated by substance P. *J Immunol* **162**:1656-1661.

Remröd C, Lonne-Rahm S and Nordliond K (2007) Study of substance P and its receptor neurokinin-1 in psoriasis and their relation to chronic stress and pruritus. *Arch Dermatol Res* **299**:85-91.

Rivera J, Fierro NA, Olivera A and Suzuki R (2008) New insights on mast cell activation via the high affinity receptor for IgE. *Adv Immunol* **98**:85-120.

Rodewald HR, Dessing M, Dvorak AM and Galli SJ (1996) Identification of a committed precursor for the mast cell lineage. *Science* **271**:818-822.

Salamon P, Shoham NG, Gavrieli R, Wolach B and Mekori YA (2005) Human mast cells release interleukin-8 and induce neutrophil chemotaxis on contact with activated T cells. *Allergy* **60**:1316-1319.

Saleiro D and Platanias LC (2015) Intersection of mTOR and STAT signaling in immunity. *Trends Immunol* **36**:21-29.

Schmetzer O, Valentin P, Church MK, Maurer M and Siebenhaar F (2016) Murine and human mast cell progenitors. *Eur J Pharmacol* **778**:2-10.

Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, Donald-Smith GP, Gao H, Hennessy L, Finnerty CC, Lopez CM, Honari S, Moore EE, Minei JP, Cuschieri J, Bankey PE, Johnson JL, Sperry J, Nathens AB, Billiar TR, West MA, Jeschke MG, Klein MB, Gamelli RL, Gibran NS, Brownstein BH, Miller-Graziano C, Calvano SE, Mason PH, Cobb JP, Rahme LG, Lowry SF, Maier RV, Moldawer LL, Herndon DN, Davis RW, Xiao W and Tompkins RG (2013) Genomic responses in mouse models poorly mimic human inflammatory diseases. *Proc Natl Acad Sci U S A* **110**:3507-3512.

Siegel AM, Stone KD, Cruse G, Lawrence MG, Olivera A, Jung MY, Barber JS, Freeman AF, Holland SM, O'Brien M, Jones N, Nelson CG, Wisch LB, Kong HH, Desai A, Farber O, Gilfillan AM, Rivera J and Milner JD (2013) Diminished allergic disease in patients with STAT3 mutations reveals a role for STAT3 signaling in mast cell degranulation. *J Allergy Clin Immunol* **132**:1388-1396.

Skaper SD, Facci L and Giusti P (2014) Mast cells, glia and neuroinflammation: partners in crime? *Immunology* **141**:314-327.

Smrz D, Cruse G, Beaven MA, Kirshenbaum A, Metcalfe DD and Gilfillan AM (2014) Rictor negatively regulates high-affinity receptors for IgE-induced mast cell degranulation. *J Immunol* **193**:5924-5932.

Smrz D, Kim MS, Zhang S, Mock BA, Smrzova S, DuBois W, Simakova O, Maric I, Wilson TM, Metcalfe DD and Gilfillan AM (2011) mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells. *Blood* **118**:6803-6813.

Sumpter TL, Ho CH, Pleet AR, Tkacheva OA, Shufesky WJ, Rojas-Canales DM, Morelli AE and Larregina AT (2015) Autocrine hemokinin-1 functions as an endogenous adjuvant for IgE-mediated mast cell inflammatory responses. *J Allergy Clin Immunol* **135**:1019-1030.

Takayama G, Ohtani M, Minowa A, Matsuda S and Koyasu S (2013) Class I PI3K-mediated Akt and ERK signals play a critical role in FcepsilonRI-induced degranulation in mast cells. *Int Immunol* **25**:215-220.

Taliou A, Zintzaras E, Lykouras L and Francis K (2013) An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders. *Clin Ther* **35**:592-602.

Theoharides T.C., Asadi S. and Panagiotidou S (2012) A case series of a luteolin formulation (Neuroprotek®) in children with autism spectrum disorders. *Intl J Immunopathol Pharmacol* **25**:317-323.

Theoharides TC, Alysandratos KD, Angelidou A, Delivanis DA, Sismanopoulos N, Zhang B, Asadi S, Vasiadi M, Weng Z, Miniati A and Kalogeromitros D (2012) Mast cells and inflammation. *Biochim Biophys Acta* **1822**:21-33.

Theoharides TC and Cochrane DE (2004) Critical role of mast cells in inflammatory diseases and the effect of acute stress. *J Neuroimmunol* **146**:1-12.

Theoharides TC, Sieghart W, Greengard P and Douglas WW (1980) Antiallergic drug cromolyn may inhibit histamine secretion by regulating phosphorylation of a mast cell protein. *Science* **207**:80-82.

Theoharides TC, Tsilioni I, Patel AB and Doyle R (2016) Atopic diseases and inflammation of the brain in the pathogenesis of autism spectrum disorders. *Transl Psychiatry* **6**:e844.

Theoharides TC, Valent P and Akin C (2015) Mast Cells, Mastocytosis, and Related Disorders. *N Engl J Med* **373**:163-172.

Theoharides TC, Zhang B, Kempuraj D, Tagen M, Vasiadi M, Angelidou A, Alysandratos KD, Kalogeromitros D, Asadi S, Stavrianeas N, Peterson E, Leeman S and Conti P (2010) IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. *Proc Natl Acad Sci U S A* **107**:4448-4453.

Tsilioni I, Dodman N, Petra AI, Taliou A, Francis K, Moon-Fanelli A, Shuster L and Theoharides TC (2014) Elevated serum neurotensin and CRH levels in children with autistic spectrum disorders and tail-chasing Bull Terriers with a phenotype similar to autism. *Transl Psychiatry* **4**:e466.

Tsilioni I, Russell IJ, Stewart JM, Gleason RM and Theoharides TC (2016) Neuropeptides CRH, SP, HK-1, and Inflammatory Cytokines IL-6 and TNF Are Increased in Serum of Patients with Fibromyalgia Syndrome, Implicating Mast Cells. *J Pharmacol Exp Ther* **356**:664-672.

Vasiadi M, Therianou A, Sideri K, Smyrnioti M, Delivani D, Sismanopoulos N, Asadi S, Katsarou-Katsari A, Petrakopoulou D, Theoharides A, Antoniou C, Stavrianeas N, Kalogeromitros D and Theoharides TC (2012) Increased serum CRH levels with decreased skin CRH-R1 gene expression in psoriasis and atopic dermatitis. *J Allergy Clin Immunol* **129**:1410-1413.

Vieira Dos SR, Magerl M, Martus P, Zuberbier T, Church MK, Escribano L and Maurer M (2010) Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus. *Br J Dermatol* **162**:674-676.

Walle T (2007) Methylation of dietary flavones greatly improves their hepatic metabolic stability and intestinal absorption. *Mol Pharm* **4**:826-832.

Weichhart T, Costantino G, Poglitsch M, Rosner M, Zeyda M, Stuhlmeier KM, Kolbe T, Stulnig TM, Horl WH, Hengstschlager M, Muller M and Saemann MD (2008) The TSC-mTOR signaling pathway regulates the innate inflammatory response. *Immunity* **29**:565-577.

Weng Z, Zhang B, Asadi S, Sismanopoulos N, Butcher A, Fu X, Katsarou-Katsari A, Antoniou C and Theoharides T (2012) Quercetin is more effective than cromolyn in blocking human mast cell cytokine release and inhibits contact dermatitis and photosensitivity in humans. *PloS One* **7**:e33805-k.

Weng Z, Patel AB, Panagiotidou S and Theoharides TC (2015) The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells. *J Allergy Clin Immunol* **135**:1044-1052.

Williamson G and Manach C (2005) Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies. *Am J Clin Nutr* **81**:243S-255S.

Willsey AJ and State MW (2015) Autism spectrum disorders: from genes to neurobiology. *Curr Opin Neurobiol* **30**:92-99.

Xagorari A, Papapetropoulos A, Mauromatis A, Economou M, Fotsis T and Roussos C (2001) Luteolin inhibits an endotoxin-stimulated phosphorylation cascade and proinflammatory cytokine production in macrophages. *J Pharmacol Exp Ther* **296**:181-187.

Yang Y, Heo P, Kong B, Park JB, Jung YH, Shin J, Jeong C and Kweon DH (2015) Dynamic light scattering analysis of SNARE-driven membrane fusion and the effects of SNARE-binding flavonoids. *Biochem Biophys Res Commun* **465**:864-870.

Zhang B, Asadi S, Weng Z, Sismanopoulos N and Theoharides TC (2012a) Stimulated human mast cells secrete mitochondrial components that have autocrine and paracrine inflammatory actions. *PloS One* **7**:e49767.

Zhang S, Zeng X, Yang H, Hu G and He S (2012b) Mast cell tryptase induces microglia activation via protease-activated receptor 2 signaling. *Cell Physiol Biochem* **29**:931-940.

JPET #240564

Footnotes

This work was supported in part by a grant from the Jane Botsford Johnson Foundation (Theoharides) and a pre-doctoral fellowship from the Nancy Lurie Marks Family Foundation (Patel). There is no direct conflict to disclosure. The following US patents were recently awarded to the senior and corresponding author (TCT) who has signed an agreement with Tufts: US 9,050,275 - Methods of Treating ASD and Compositions for Same; US 13/009,282 (allowed) Methods of Screening for and Treating ASD and Compositions for Same.

Legends for Figures

Figure 1. Inhibitors of mTOR signaling dose-dependently decrease SP-stimulated pro-inflammatory mediator release from human MC. LAD2 MC (0.5×10^6 cells) were pre-treated with the mTOR inhibitor, rapamycin (0.05-0.2 µM, 24 h), the ATP-competitive mTOR inhibitor, Torin1 (0.05-0.2 µM, 24 h) prior to stimulation with SP (1 µM) for 24 h to measure release of **(A)** TNF and **(B)** CXCL8 by ELISA. LAD2 MC (0.5×10^6 cells) were also pre-treated with the upstream **(C)** PI3K inhibitor LY294002 (1-10 µM, 2 h), prior to stimulation with SP (1 µM) for 24 h to measure release of TNF and CXCL8 mediators. All inhibitors were dissolved in water or DMSO with final concentration < 0.1 %. All conditions were performed in triplicates for each data set and were repeated three times (n=3), with results presented as mean ± SD. Significance of comparisons were made for stimulated cells without any inhibitor (control) and those with inhibitor/flavonoid, as denoted by the horizontal lines, which indicate significance at p<0.001 for each comparison made. All inhibitor/flavonoid treatments were also compared among themselves and the vertical brackets indicate the corresponding levels of significance, when present [p<0.05 (*), p<0.001 (**) and p<0.0001 (***)].

Figure 2. Human MC pro-inflammatory mediator release in response to NT or SP is attenuated by PI3K/mTOR inhibitors and the flavonoids, luteolin and methoxyluteolin. LAD2 MC (0.5×10^6 cells) were pre-treated with the mTOR inhibitors [rapamycin (Rap) and Torin1, 0.2 µM, 24 h] or the upstream PI3K inhibitor [LY294002 (LY), 10 µM, 2 h] or the natural flavonoids [luteolin (Lut) and methoxyluteolin (Methlut), 50 µM, 30 mins], then stimulated with NT (10 µM) **(A-C)** or the positive control trigger SP (1 µM) **(D-F)** for 24 h to measure release of TNF, CXCL8 and VEGF mediators by specific enzyme-linked immunosorbent assays (ELISA). All conditions were performed in triplicates for each data set and were repeated three times

(n=3), with results presented as mean ± SD. Significance of comparisons were made for stimulated cells without any inhibitor (control) and those with inhibitor/flavonoid, as denoted by the horizontal lines, which indicate significance at p<0.0001 for each comparison made. All inhibitor/flavonoid treatments were also compared among themselves and the horizontal brackets indicate the corresponding levels of significance, when present [p<0.05 (*), p<0.001 (**) and p<0.0001 (***)].

Figure 3. Human LAD2 MC pro-inflammatory mediator gene expression in response to NT or SP is inhibited by the PI3K/mTOR inhibitors, luteolin and methoxyluteolin. LAD2 MC (1x10^6 cells) were pre-treated with the mTOR inhibitors [rapamycin (Rap) and Torin1, 0.2 µM, 2 or 24 h] or the upstream PI3K inhibitor [LY294002 (LY), 10 µM, 2 h] or the natural flavonoids [luteolin (Lut) and methoxyluteolin (Methlut), 50 µM, 30 mins], prior to stimulation with NT (10 µM) **(A-C)** or the positive control trigger SP (1 µM) **(D-F)** for 6 h to measure gene expression of TNF, CXCL8 and VEGF by RT-qPCR. All inhibitors were dissolved in water or DMSO with final concentration < 0.1 %. All conditions were performed in triplicates for each data set and were repeated three times (n=3), with results presented as mean ± SD. Significance of comparisons were made for stimulated cells without any inhibitor (control) and those with inhibitor/flavonoid, as denoted by the horizontal lines, which indicate significance at p<0.0001 for each comparison made. All inhibitor/flavonoid treatments were also compared among themselves and the horizontal brackets indicate the corresponding levels of significance, when present [p<0.05 (*), p<0.001 (**) and p<0.0001 (***)].

Figure 4. NT and SP stimulate mTOR activation in human LAD2 MC. LAD2 MC (1x10^6 cells) were stimulated with NT (10 µM) **(A-C)** or the positive control trigger SP (1 µM) **(D-F)** for 0-60

mins to probe for the total and phosphorylated levels of mTOR, and substrates p70S6K and 4EBP1 by Western blot analysis; peak mTOR activation was denoted at 20 min for pmTORSer2448 and pp70S6KThr389 proteins, while the levels of p4EBP1Thr37/46 protein remained unchanged. Results were quantified using densitometric analyses for pmTORSer2448 to mTOR levels **(B, D)** and pp70S6KThr389 to p70S6K levels **(B, E)** in response to NT (10 µM) or SP (1 µM). All conditions were performed in triplicates for each data set, repeated three times (n=3), with results presented as mean ± SD. Significance of comparisons were made for unstimulated cells without NT or SP treatment and those with stimulation by the neuropeptides, as denoted by $p<0.05$ (*), $p<0.001$ (**) and $p<0.0001$ (***).

Figure 5. NT- or SP-stimulated mTOR activation in LAD2 MC is inhibitable by luteolin and methoxyluteolin. LAD2 MC (1×10^6 cells) were pre-treated with the mTOR inhibitors [rapamycin, (Rap) and Torin1, 0.2 µM, 24 h] or the upstream PI3K inhibitor [LY294002 (LY), 10 µM, 2 h] or the natural flavonoids [luteolin (Lut) and methoxyluteolin (Methlut), 10 or 50 µM, 30 mins], prior to stimulation with **(A-C)** NT (10 µM) or **(D-F)** SP (1 µM) for 20 min to probe for the total and phosphorylated levels of mTOR, and substrates p70S6K and 4EBP1 by both phospho-ELISA kits and Western blot analysis (lower panel). The protein levels of mTOR and pmTOR Ser2448 **(A, D)** and the downstream mTORC1 substrates, p70S6K and pp70S6K Thr389 **(B, E)** and, 4EBP1 and p4EBP1 Thr37/46 **(C, F)** were measured using specific total or phospho-ELISA kits for equal amounts of protein lysates, with ratios of phosphorylated to total proteins normalized. All conditions were performed in triplicates for each data set and were repeated three times (n=3), with results presented as mean ± SD. Significance of comparisons were made for stimulated cells without any inhibitor (control) and those with inhibitor/flavonoid, as denoted by the horizontal lines, which indicate significance at $p<0.0001$ for each comparison made. All inhibitor/flavonoid treatments were also compared among themselves and the horizontal

brackets indicate the corresponding levels of significance, when present [p<0.05 (*), p<0.001

(**) and p<0.0001 (***)].

JPET #240564
Article Title: Methoxyluteolin inhibits neuropeptide-stimulated TNF, CXCL8 and VEGF release via mTOR activation from human mast cells
Authors: Arti B. Patel and Theoharis C. Theoharides

## Figures

Figure 1

A

B

C

JPET #240564
Article Title: Methoxyluteolin inhibits neuropeptide-stimulated TNF, CXCL8 and VEGF release via mTOR activation from human mast cells
Authors: Arti B. Patel and Theoharis C. Theoharides

Figure 2

JPET #240564
Article Title: Methoxyluteolin inhibits neuropeptide-stimulated TNF, CXCL8 and VEGF release via mTOR
activation from human mast cells
Authors: Arti B. Patel and Theoharis C. Theoharides

Figure 3

JPET #240564
Article Title: Methoxyluteolin inhibits neuropeptide-stimulated TNF, CXCL8 and VEGF release via mTOR
activation from human mast cells
Authors: Arti B. Patel and Theoharis C. Theoharides

Figure 4

JPET #240564
Article Title: Methoxyluteolin inhibits neuropeptide-stimulated TNF, CXCL8 and VEGF release via mTOR activation from human mast cells
Authors: Arti B. Patel and Theoharis C. Theoharides

Figure 5